Skip to content
Search our Site
Search our site
Search our site
My PD Journey
About the EPDA
Political affairs and policy
All research papers
Search research papers
Resources and publications
Medication research papers
Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients
Conclusion: Our exploratory analyses suggest that optimizing levodopa delivery with levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson's disease.
15 May 2016
Levodopa responsiveness of dysphagia in advanced Parkinson's disease and reliability testing of the FEES-Levodopa-test
Conclusions: A significant proportion of advanced PD patients with motor fluctuations and mild to moderate oropharyngeal dysphagia may demonstrate a clinically relevant improvement of swallowing after levodopa challenge. The FEES-levodopa-test is a reliable and sensitive tool to differentiate these responders from non-responders.
28 April 2016
Levodopa and neuropathy risk in patients with Parkinson disease: Effect of COMT inhibition
Results: The prevalence of neuropathy in LELD patients was 19.4% whereas it was 5.7% in LELD_ICOMT group with a significant difference (p = 0.025). In LELD_ICOMT cohort the daily LD dose and serum VB12 levels were significantly higher (p < 0.0001), the serum Hcy levels were significantly lower (p = 0.001) compared to LELD group.
20 April 2016
A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease
Results: Eighty-six patients used the study drug at an average frequency of 2.1 times per day for CVT-301 and for placebo. At 4 weeks, least-squares mean change in UPDRS Part III score favored CVT-301 by 7.0 points (P < 0.001). A treatment effect was evident at 10 minutes. At 4 weeks, least-squares mean OFF-time change from baseline favored CVT-301 by 0.9 hours per day (P = 0.045). The most frequently reported adverse events in the CVT-301 group were dizziness, cough, and nausea, each in 7% (3 of 43 patient
19 April 2016
Use of antidepressants in Parkinson's disease: A Swedish register-based study of over 1.5 million older people
Results: Twenty-two percent of the home-dwellers and 50% of the institutionalized elderly persons with APD used antidepressants. Persons with APD had a higher probability of use of any antidepressant compared to persons without APD. A selective serotonin reuptake inhibitor (SSRI) was the most commonly used antidepressants in both settings followed by mirtazapin.
18 April 2016
Integrated Safety of Levodopa-Carbidopa Intestinal Gel From Prospective Clinical Trials
In the largest collection of levodopa-carbidopa intestinal gel safety data from prospective clinical studies, procedure/device events were frequently reported and occasionally life threatening. Most non-procedure/device events were typical for levodopa treatment and an elderly population. These factors combined with high treatment efficacy led to a relatively low discontinuation rate in advanced PD patients.
15 April 2016
Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort study
OPTIPUMP was a prospective, open-label, observational cohort study involving 30 investigational sites in France. CSAI was proposed as part of routine clinical care to patients aged 18 years, in absence of dementia, with a PD diagnosis and based on the presence of motor fluctuations not controlled by oral treatments.
08 April 2016
Gender and non motor fluctuations in Parkinson's disease: A prospective study
The study showed that female gender represents a major risk factor for the development of NMF. There were no gender differences in medication intake, thus NMF in women remain mostly underestimated and not properly treated. From a practical standpoint, clinicians should take into account the role of gender in the management of NMF in PD.
04 April 2016
Pioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammation
By triggering a mitochondrial Complex IV defect in dopaminergic neurons, authors created a new mouse model resembling the late stages of PD with massive degeneration of dopaminergic neurons and striatal dopamine depletion. The motor phenotypes were improved by Pioglitazone treatment, suggesting that targetable secondary pathways can influence the development of certain forms of PD.
02 April 2016
Lithium Use in Older Adults is Associated with Increased Prescribing of Parkinson Medications
For patients with no previous antipsychotic use, lithium monotherapy was associated with an increased incidence of dopaminergic drug use (adjusted HR: 1.87; 95% CI: 1.063.30) and an increased incidence of antiparkinson drug use or a PD diagnosis (adjusted HR: 1. 68; 95% CI: 1.132.48) compared with antidepressant monotherapy.
01 April 2016
Back to Top
Add page to PDF basket
Copyright © 2016 EPDA. All Rights Reserved.
Privacy and cookies